Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Prweb

Published November 2, 2026 · Updated November 3, 2026

Ohio State Study Follows VETS Grant Recipients for Nine Months After Psychedelic Treatment

Read the full story at Prweb

Psychedelic Drug Research and Education. Published in Chronic Stress, the study followed 113 U.S. military veterans who received VETS Foundational.

Surfaced by 2 Google Alerts

  • Psychedelics
  • Psychedelic press release